PIK3CA and cervical carcinoma: The two patients with cervical cancer treated with everolimus who achieved disease stabilization that lasted longer than 6 months had either a PIK3CA mutation (Glu542Lys) or a PTEN heterozygous deletion with a loss of protein expression (Table 2 and Data Supplement).